Chiron Corporation

Bayer Aktiengesellschaft

Novartis Vaccines & Diagnostics, Gmbh

Bayer Pharmaceuticals Corporation

Bayer Pharmaceutical Corporation

Nathalie Dubois-Stringfellow

John E Murphy

Ronald N Zuckermann

Michael A Innis

Fred Ehrenkranz Cohen

Tetsuo Uno

Varavani J Dwarki

Toshihiko Takeuchi

Dmitry Zubov

Julie Rinkenberger

Jeffrey Tepper

Gustav Hagen

Maresa Wick

Delanie Cassell

Isa Samuels

Gabi Friedrich

This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.

Compositions and methods for polynucleotide delivery

The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP (SEQ ID NO: 118) repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP (SEQ ID NO: 118) repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP (SEQ ID NO: 119)). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods. An example is also provided where a human anti-MN IgG1 mediates tumor cell lysis though antibody-dependent cell-mediated cytotoxicity. Therefore, these antibodies will be useful for the treatment of cancers in which MN is upregulated or can be useful for the diagnosis of cancers in which MN is upregulated.

Human antibodies that have MN binding and cell adhesion-neutralizing activity

A purifiedenvelope protein termed 'B2L' can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response to the B2L protein.

Use of Parapox B2L protein to treat cancer and modify immune responses

The present invention provides methods for modulating angiogenesis by administering anti-angiogenic Ang-7 polypeptides to a subject. Methods of modulating angiogenesis by administering an anti-angiogenic ANG-7 nucleic acid are also provided.

Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor

Polycationic polymers

Growing community of inventors

Berkeley, CA, United States of America

Nathalie Dubois-Stringfellow